Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Motohiko, Tokuhisa"'
Autor:
Daisuke Takakura, Shoko Ohashi, Noritoshi Kobayashi, Motohiko Tokuhisa, Yasushi Ichikawa, Nana Kawasaki
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Aberrant glycosylation is a prominent feature of cancer, that can be used as targets to improve the existing cancer biomarkers, and help to assess metastasis risks, and therapeutic effects. We developed a targeted O-glycoproteomics method using serum
Externí odkaz:
https://doaj.org/article/03d138c1794e4268b1b706c478a2f799
Autor:
Naoki Hamada, Ayaka Maeda, Kaoru Takase-Minegishi, Yohei Kirino, Yumiko Sugiyama, Ho Namkoong, Nobuyuki Horita, Ryusuke Yoshimi, Hideaki Nakajima, YCU irAE Working Group, Motohiko Tokuhisa, Keiichi Kondo, Noboru Nakaigawa, Nobuaki Kobayashi, Daisuke Sano, Maki Hagihara, Nobuhiko Oridate, Takeshi Kaneko, Yukie Yamaguchi, Masahiro Yao, Yasushi Ichikawa
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Immune checkpoint inhibitor (ICI)-related myositis is a rare, potentially fatal condition that warrants further studies. Its incidence, clinical features, and prognosis remain poorly understood. To address these gaps, we conducted a systematic review
Externí odkaz:
https://doaj.org/article/38aec02d7cfc43e2832c88df98da9512
Autor:
Yusuke, Kurita, Noritoshi, Kobayashi, Kazuo, Hara, Nobumasa, Mizuno, Takamichi, Kuwahara, Nozomi, Okuno, Shin, Haba, Motohiko, Tokuhisa, Sho, Hasegawa, Takamitsu, Sato, Kunihiro, Hosono, Shingo, Kato, Takaomi, Kessoku, Itaru, Endo, Yasuhiro, Shimizu, Kensuke, Kubota, Atsushi, Nakajima, Yasushi, Ichikawa, Yasumasa, Niwa
Publikováno v:
Internal Medicine. 62:159-167
Objective The effectiveness of everolimus for the management of pancreatic neuroendocrine neoplasms (PNENs), including the G3/NEC types, remains unclear. We therefore investigated the effectiveness of the drug for the management of PNENs. Methods We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8fb2d99e7be80d8d2d6dbcb4d36d12f
https://doi.org/10.2169/internalmedicine.9416-22
https://doi.org/10.2169/internalmedicine.9416-22
Autor:
Takaomi Kessoku, Noritoshi Kobayashi, Masato Yoneda, Yuki Kasai, Anna Ozaki, Naoki Okubo, Michihiro Iwaki, Takashi Kobayashi, Tsutomu Yoshihara, Yusuke Kurita, Yasushi Honda, Motohiko Tokuhisa, Hiroto Ishiki, Takashi Hibiya, Satoshi Fujii, Atsushi Nakajima, Yasushi Ichikawa
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Neuroendocrine tumors (NETs) are rare, but their worldwide incidence is gradually increasing. NETs are generally heterogeneous; however, in rare cases, they have been shown to change their phenotype (i.e., nonfunctional to functional or o
Externí odkaz:
https://doaj.org/article/2eb8a6c882d14ce69f1ebbe3db7a698b
Autor:
Daisuke, Sano, Motohiko, Tokuhisa, Hideaki, Takahashi, Takashi, Hatano, Goshi, Nishimura, Yasushi, Ichikawa, Nobuhiko, Oridate
Publikováno v:
Anticancer Research. 42:4477-4484
This Japanese single-center retrospective cohort study aimed to evaluate the real-world therapeutic outcomes of pembrolizumab or pembrolizumab plus chemotherapy (pembrolizumab regimen) as first-line therapy for patients with recurrent/metastatic squa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8cb32f8d2b97bd233a142ec458d100
https://doi.org/10.21873/anticanres.15948
https://doi.org/10.21873/anticanres.15948
Publikováno v:
Case Reports in Oncology, Vol 9, Iss 1, Pp 134-137 (2016)
A 49-year-old Japanese man had multiple huge masses (max. size 60 mm diameter) in his liver. These tumors were pathologically diagnosed by tumor biopsy as epithelioid hemangioendotheliomas of the liver. In this case, multiple liver tumors existed in
Externí odkaz:
https://doaj.org/article/ea021184726c4b7582ccc2b6921680ff
Autor:
Yuhan Rong, Naoki Okubo, Risa Fukui, Akihiro Suzuki, Motokazu Sato, Motohiko Tokuhisa, Yuma Takeda, Noritoshi Kobayashi, Itaru Endo, Yasushi Ichikawa
Publikováno v:
Cancer Research. 83:879-879
Background: Exosomal mRNAs secreted from cancer cells are regarded as important messengers in communication system between cells. In PC, some exosomal RNAs from patients’ plasma were expected as biomarkers of PC. However, exosomes in the blood of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ab97b875c22db1848604c3af750fa4a
https://doi.org/10.1158/1538-7445.am2023-879
https://doi.org/10.1158/1538-7445.am2023-879
Autor:
Naoki Okubo, Shoko Takano, Yasushi Ichikawa, Noritoshi Kobayashi, Matsuyoshi Ogawa, Kenichi Ito, Motohiko Tokuhisa, Tomohiro Kaneta, Makoto Hosono, Madoka Sugiura, Daisuke Utsunomiya, Seigo Kinuya, Yuma Takeda, Masaharu Hata, Akihiro Suzuki, Tomio Inoue
Publikováno v:
Annals of Nuclear Medicine
Purpose Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive neuroendocrine tumors (NETs) with somatostatin receptor expression. We have, f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20f84ccd0dbf196ab839ea2500e04b29
http://europepmc.org/articles/PMC8557155
http://europepmc.org/articles/PMC8557155
Autor:
Takeshi Shimamura, Shoko Takano, Noritoshi Kobayashi, Naoki Okubo, Yasushi Ichikawa, Yuma Takeda, Akihiro Suzuki, Motohiko Tokuhisa, Felix Kaul, Damian Wild
Publikováno v:
Journal of Hepato-Biliary-Pancreatic Sciences. 28:727-739
Background Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is an innovative treatment for advanced somatostatin-positive neuroendocrine tumors (NETs). PRRT cannot be performed in Japan because there is no approval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ca3ec444c1936bacdb1624d50005dfb
https://doi.org/10.1002/jhbp.1014
https://doi.org/10.1002/jhbp.1014
Autor:
Kunihiro Hosono, Atsushi Nakajima, Itaru Endo, Yusuke Kurita, Takamitsu Sato, Ayumu Goto, Noritoshi Kobayashi, Sho Hasegawa, Motohiko Tokuhisa, Yasushi Ichikawa, Naoki Okubo
Publikováno v:
Internal Medicine
Objective Neuroendocrine neoplasms (NENs) are rare and indolent diseases, but the efficacy of treatment without surgical resection is temporary and limited. Targeted immunotherapy is an important treatment strategy in several cancers. However, the tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fdd1fbf14cdd13a220468bc58cd2d82
http://europepmc.org/articles/PMC8079921
http://europepmc.org/articles/PMC8079921